Three insights:
1. Titan’s Probuphine subdermal implant is developed to deliver buprenorphine continuously for six months post-insertion to combat addiction for patients with opioid use disorder.
2. The company anticipates most U.S. Probuphine sales to be through the specialty pharmacy distribution system.
3. The expansion of its specialty pharmacy network is crucial in the commercial plan tasked with expediting patient access to treatment by making product ordering and product easier.
“We believe this expansion will enhance the ability of eligible patients suffering from OUD to gain better access to long-term maintenance treatment with Probuphine,” said Titan’s Executive Vice President and Chief Commercial Officer, Dane Hallberg.
More articles on practice management:
Coordinated Health opens new orthopedic facility in Pennsylvania
New Mexico Orthopaedics plans to help revitalize shopping mall — 3 details
Northwestern creates Hispanic Brain and Spine Tumor Program — 3 insights
